Article
Cancer is present in 15% of men with 'normal' PSAs and DREs; 2% have high-grade disease
Clinical Forum: Advances in low-grade UTUC treatment and care
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC